N/A N=257 Down Syndrome Metabolic Health Study
Down Syndrome · Trisomy 21
Primary: Non-HDL Cholesterol — 128; 107 mg/dl
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 Choline and Cardiometabolic Health
Cardiovascular Risk Factor
Primary: Change From Baseline in Insulin Sensitivity at 4 Weeks — 0.28; -0.29 Calculated Ratio - No units
N/A N=47 Healthy Bodies, Healthy Kids
Child Mental Disorders · Obesity · Metabolic Syndrome
Primary: DEXA-measured Adiposity — 0.76; -0.43; -2.79 kilograms — p=0.01
N/A N=193 Cardiac CT's Role in Asymptomatic Patients With Diabetes and Metabolic Syndrome
Diabetes · Metabolic Syndrome
Primary: Systolic BP Pressure — 145; 144 mm Hg
N/A N=314 Reducing Cardiometabolic Risk and Promoting Functional Health in Older Adults With Obesity and Prediabetes
Obesity · PreDiabetes · Aging
Primary: Change in Bodyweight — -7.4; -6.1 percentage of bodyweight change — p=0.196
N/A N=80 Improving Metabolic Health in Patients With Diastolic Dysfunction
Obesity · Heart Failure, Diastolic · Metabolic Syndrome
Primary: Change From Baseline at 1 Year in Myocardial Lipid Content — -0.16; -0.18; -0.53; -0.19 %fat/water
N/A N=45 PilAm Go4Health Weight Loss Program to Prevent Heart Disease
Type2 Diabetes
Primary: Feasibility for Participant Enrollment and Retention — 22; 23 percentage of participants retained
N/A N=60 Evaluation of Group Lifestyle Balance Maintenance Strategies
Diabetes
Primary: Change in Weight — 2.1; 0.2 pounds
N/A N=44 Biomarkers of Cardiometabolic Risk in Children Treated With Antipsychotics: A Preliminary Study of Direct Measures
Mental Disorders
Primary: Carotid Artery Intima-media Thickness Measured by Ultrasonography. — 0.508; 0.519 millimeters — p=0.49
N/A N=34 Nuts and Oil Pilot Study
Metabolic Syndrome
Primary: Proportion of Participants With MetS With Epigenetic Age Acceleration — 0.21; 0.53 proportion of participants AgeAccelGrim>
N/A N=28 Relative Sarcopenia and Cardiometabolic Risk in Young Adults With Obesity
Overweight and Obesity · Insulin Resistance
Primary: Percent Change in Serum Myostatin Levels From Pre- to 3 Hours Post-exercise — -6.9; 8.5 % change in serum myostatin — p=0.303
N/A N=12 Metabolic Syndrome and Fall Risk
Metabolic Syndrome · Autonomic Neuropathy
Primary: Four Square Step Test (FSST) — 11.04; 14.29 seconds
N/A N=36 Exercise,Metabolic Syndrome and Weight Regain (Echocardiography Substudy)
Metabolic Syndrome · Obesity
Primary: Mean Resting E/E' — 7.01 ml/min/kg — p==0.14
N/A N=32 Cardiometabolic Benefits of Potatoes Mediated Along the Gut-Vessel Axis in Adults With Metabolic Syndrome
Cardiovascular Diseases · Endotoxemia · Endothelial Dysfunction
Primary: Endotoxin — 21.2; 23.3 EU/mL
N/A N=13 The Effects of Altering Physical Activity on Cardiometabolic Health
Insulin Resistance
Primary: Effects of Physical Inactivity on Post Prandial Blood Flow — 0 percentage of change in blood flow
Phase 2 N=405 Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome
Metabolic Syndrome
Primary: Blood Glucose Level — 6.05; 6.43; 4.58; 14.5 mmole/L
Phase 3 N=103 Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes
Diabetes · Hypertension · Dyslipidemia
Primary: Percent of Patients Achieving Hemoglobin A1C Goal, LDL Cholesterol Goal, and Systolic Blood Pressure Goal From the Enrollment Until the End of the Study — 40.8; 20.4…
N/A N=21,664 Pre-Diabetes Cardiovascular (CV) Care (Pre-Diabetes Wizard)
Pre-diabetes
Primary: Predicted Annual Rate of Change in 10 Year Risk of Fatal or Nonfatal Heart Attack or Stroke — 1.100; 1.096 units on a scale — p=<0.05
N/A N=293 Canadian Health Advanced By Nutrition and Graded Exercise
Metabolic Syndrome
Primary: Feasibility of the Diet Intervention — 4782 prescribed diet visits
Phase 3 N=91 Exercise Dose and Metformin for Vascular Health in Metabolic Syndrome
Metabolic Syndrome
Primary: Change in Fasting Unscaled Flow Mediated Dilation (FMD) of the Brachial Artery — -0.45; 0.76; 3.50; 5.28 Percent change in diameters — p=0.045
Phase 2 N=125 PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction
Healthy · Obese
Primary: Resting Energy Expenditure After 12 Weeks of Drug Therapy (kcal/Day) — 1267; 1268 kcal/day
Phase 2 N=138 Cardiometabolic Effects of Pecans as a Snack
Cardiovascular Diseases
Primary: Flow Mediated Dilation — 7.07; 7.25 percent point change in arterial diamete
N/A N=143 SomaSignal Tests on Medical Management and Change in Risk in Patients With Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Participants With Type 2 Diabetes (T2D) Who Had Prescription Changes in Concordance With SSCVD Results — 45; 13; 8; 35 Participants
N/A N=100 Inflammation and the Metabolic Syndrome in Humans
Metabolic Syndrome X
Primary: The Primary Outcome Measure is Plasma Levels of TNF Alpha. — 507 ng/mL
N/A N=24 Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome
HIV Infections · Cardiovascular Disease · Insulin Resistance
Primary: Myocardial Glucose Utilization Rate — 109.6; 106.7; 109.1; 87.2 (nmol glucose/g heart muscle/min
N/A N=116 Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
Metabolic Syndrome X · Overweight · Hypertension
Primary: Change in Carotid Intima-media Thickness From Baseline to Year 1 — 0.766; 0.765; 0.758; 0.768 millmeter — p=0.7279
N/A N=53 Evaluation of Pulse Fibre Supplementation on Obesity and the Metabolic Syndrome
Obesity
Primary: Change in Fat Mass at 12 Weeks — -0.74; 0.42 kg
Phase 4 N=36 Oral Contraceptives in the Metabolic Syndrome
Metabolic Syndrome X · Insulin Resistance · Obesity
Primary: Changes in Insulin Sensitivity Associated With Oral Contraceptive (OC) Use Compared Among (1) Obese Women and (2) Lean Women — 4.36; 6.62; 3.82; 8.23 mIU/L
Phase 2 N=40 Implications for Treatment of the Metabolic Syndrome
Metabolic Syndrome
Primary: Muscle Microvascular Function — 3.7; 4.0 10^3 mL*min^-1*100ml^-1*mmHg^-1
N/A N=66 Study of Serum Markers for Cardiovascular Risk in Obese Youth and Impact of Lifestyle and Medication Intervention
Obesity
Primary: Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) at 6 Months — -0.37; -1.78; -0.29; 0.00 mg/dL